MELI vs STRO · P/E 43, rev $20.78B vs rev $62.0M
MercadoLibre Inc. (MELI) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
MercadoLibre Inc. (MELI) is a internet retail company listed on NASDAQ.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported MELI revenue for 2024-12-31 was $20.78B. Net income was $1.91B. Revenue was up 387.6% from 2023-12-31 to 2024-12-31. MELI currently screens at market cap $82.73B and trailing P/E 43.1.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
MELI currently screens at market cap $82.73B and trailing P/E 43.1. STRO currently screens at market cap $470.8M.
Not investment advice. Open the MELI and STRO stock pages for the full models.
Not investment advice.